The development of AAV2-CNTF (NSR-CNTF) gene therapy for retinitis pigmentosa was also discontinued prior to Phase 3 trials because it failed to demonstrate sufficient therapeutic efficacy in earlier clinical stages. This evidence concerns the gene CNTF and retinitis pigmentosa.